Professor Kim Cheol-ho (right) of Seoul National University Bundang Hospital (right) and Han-soo Kim (left), chairman of the Korean Society of Clinical Cycling, are giving a lecture at the `Online Symposium on the 10th Anniversary of Kanab Release` held on the 3rd. Boryeong Pharmaceutical announced on the 4th that it held a symposium for the 10th anniversary of the release of Kanab, a new domestic drug, online on the 3rd.
This online symposium was mainly conducted with a 10th anniversary video screening and a Kanab academic lecture.
First, the 10th anniversary video was drawn in chronological order using calligraphy to describe the history, major achievements, and direction of Kanab’s 10 years since its release in March 2011. By ending the video with the brush character’accompaniment’, Boryeong Pharmaceutical expressed its intention to continue with customers and patients in the future.
In the academic lecture that followed, Han-soo Kim, chairman of the Korean Society of Clinical Cyclology, chaired the chair, and Professor Cheol-ho Kim of Seoul National University Bundang Hospital served as a speaker and gave a lecture on the theme of’Kannab, the 10th Anniversary of the Release: Aiming to Minimize Cardiovascular Disease in an Older Society’. The lecture introduced Kanab’s role and direction in the treatment and management of elderly hypertensive patients. After the lecture, questions and answers continued in real time. The symposium ended successfully with 3,475 simultaneous users.
In addition, Boryeong Pharmaceutical plans to hold the offline’Kannab Release 10th Anniversary Symposium’ on March 24 in compliance with the guidelines for social distancing. The Kanab Family recorded a domestic prescription record of 103.9 billion won last year (based on U-Bist, including Donghwa Pharm’s Lacor), showing a 21% increase from the previous year.
In particular, it achieved the goal of ‘100 billion won in annual prescription performance’, establishing itself as a successful case of representative domestic new drugs. At the end of last year, Kanab obtained additional indications for’proteinuria reduction’ in type 2 diabetic patients as a treatment for hypertension from the Ministry of Food and Drug Safety at the end of last year, and at the same time, it was approved to change the license for expanding the age of use. Seems to be.
Ahn Jae-hyun, CEO of Boryeong Pharmaceutical said, “The great achievements that Kanab Family has recorded over the past 10 years would not have been possible without the support and response of customers and patients in the market.” “We will continue to strive to provide various treatment options to our clients and improve the quality of life of patients.”
[정지성 기자]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]